Rômulo Carlos Dantas da Cruz
Research Subjects
Rômulo Carlos Dantas da Cruz has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ivone Antonia de Souza
Universidade Federal de Pernambuco
3 shared publications Avaniel Marinho da Silva
2 shared publications- Marcela Albuquerque de Oliveira
Universidade Federal de Pernambuco
2 shared publications - Profa. Marília Gabriela Muniz Arruda
Universidade Federal de Pernambuco
2 shared publications - Roberta Jeane Bezerra Jorge
Universidade Federal do Ceará
2 shared publications Suelen Cristina Lourenço de Barros
2 shared publications
Latest Publications
- 1 January 2024
- Published by Even3
Eficácia da humanização no atendimento a pacientes pediátricos submetidos ao tratamento radioterápico
- 1 January 2024
- Published by Even3
Eficácia da humanização no atendimento a pacientes pediátricos submetidos ao tratamento radioterápico
- 1 January 2024
- Published by Even3
Uso medicinal de Cannabis no tratamento de cefaleias: Uma revisão integrativa
- 1 January 2024
- Published by Even3
Uso medicinal de Cannabis no tratamento de cefaleias: Uma revisão integrativa
- Open Access
- 5 October 2021
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 1 (2) , 63-77
Phytochemical profile, toxicological evaluation of Rhipsalis baccifera (Sol.) Stearn (Cactaceae) extract and their antitumor activity in Ehrlich carcinoma-bearing mice
Rhipsalis baccifera (Sol.) Stearn is a typical cactus from tropical regions with wide geographic distribution, and its therapeutic potential is not yet fully understood, such as antitumoral property. Thus, this study evaluated the cytotoxic ethanolic extract of R. baccifera (EERB) and its antitumor activity against Erlich's tumor in mice. The EERB was obtained, and its phytochemical profile was filed by thin-layer chromatography. The toxicity was evaluated in vitro and in vivo using the microcrustacean Artemia salina Leach and mice. The lethal dose was determined after implantation of a tumor cell suspension, with subsequent treatment with EERB (200 mg/kg and 100 mg/kg) 48h after implantation. These values represent the tenth part of the DL50 and CL50, respectively. The presence of phenols, tannins and triterpenes were demonstrated in the phytochemical results. Toxicity was dose-dependent, and the tumor inhibition was 84.1% and 75.8% at doses of 200 mg/kg and 100 mg/kg, respectively. We can highlight that the growth of Erlich's carcinoma suffered inhibitory effects against the EERB. EERB was found to have low acute toxicity and a high potential for use in antitumor therapy. Thus, new studies involving pre-clinical and clinical analyses of the extract are essential to determine the safe dose.
- 5 October 2021
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 1 (2) , 63-77
Open AccessPhytochemical profile, toxicological evaluation of Rhipsalis baccifera (Sol.) Stearn (Cactaceae) extract and their antitumor activity in Ehrlich carcinoma-bearing mice
Rhipsalis baccifera (Sol.) Stearn is a typical cactus from tropical regions with wide geographic distribution, and its therapeutic potential is not yet fully understood, such as antitumoral property. Thus, this study evaluated the cytotoxic ethanolic extract of R. baccifera (EERB) and its antitumor activity against Erlich's tumor in mice. The EERB was obtained, and its phytochemical profile was filed by thin-layer chromatography. The toxicity was evaluated in vitro and in vivo using the microcrustacean Artemia salina Leach and mice. The lethal dose was determined after implantation of a tumor cell suspension, with subsequent treatment with EERB (200 mg/kg and 100 mg/kg) 48h after implantation. These values represent the tenth part of the DL50 and CL50, respectively. The presence of phenols, tannins and triterpenes were demonstrated in the phytochemical results. Toxicity was dose-dependent, and the tumor inhibition was 84.1% and 75.8% at doses of 200 mg/kg and 100 mg/kg, respectively. We can highlight that the growth of Erlich's carcinoma suffered inhibitory effects against the EERB. EERB was found to have low acute toxicity and a high potential for use in antitumor therapy. Thus, new studies involving pre-clinical and clinical analyses of the extract are essential to determine the safe dose.